Published in Eur J Nucl Med Mol Imaging on January 29, 2005
Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol (2007) 1.05
Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms. Eur J Nucl Med Mol Imaging (2011) 0.78
Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy. ISRN Neurol (2014) 0.75
SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias. EJNMMI Res (2013) 0.75
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci (1991) 2.26
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol (1995) 1.70
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.51
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A (1993) 1.27
Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol (1985) 1.26
Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst (1998) 1.25
[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology (1996) 1.24
Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol (1989) 1.09
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med (1998) 1.06
Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord (2002) 1.06
[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord (2001) 1.02
Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl (1997) 1.01
Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol (1998) 1.00
[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord (2000) 0.98
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol (1985) 0.96
Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med (1997) 0.94
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord (1999) 0.92
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord (1999) 0.92
123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci (2003) 0.88
Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord (2002) 0.86
[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med (1997) 0.86
Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse (2003) 0.85
Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med (1998) 0.78
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord (1998) 0.78
PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology (1999) 0.77
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
The application of graph theoretical analysis to complex networks in the brain. Clin Neurophysiol (2007) 2.20
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial. Lancet Neurol (2009) 2.01
Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry (2013) 1.52
Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil (2005) 1.52
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Frequency-dependent functional connectivity within resting-state networks: an atlas-based MEG beamformer solution. Neuroimage (2011) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry (2012) 1.47
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Cerebral impairment in chronic solvent-induced encephalopathy. Ann Neurol (2008) 1.45
Interventions for fatigue in Parkinson's disease. Cochrane Database Syst Rev (2015) 1.41
Clinical problems in the hospitalized Parkinson's disease patient: systematic review. Mov Disord (2011) 1.30
Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol (2008) 1.30
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
Pneumocephalus by Valsalva's maneuver. Neurology (2003) 1.28
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med (2008) 1.23
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry (2004) 1.15
Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend (2008) 1.14
Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. Brain (2013) 1.10
CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis (2010) 1.10
Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry (2009) 1.09
Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain (2008) 1.08
Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol (2008) 1.06
Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiol Aging (2012) 1.05
Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res (2007) 1.04
Generalized synchronization of MEG recordings in Alzheimer's Disease: evidence for involvement of the gamma band. J Clin Neurophysiol (2002) 1.04
Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab (2006) 1.03
The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology (2002) 1.03
Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder. Biol Psychiatry (2004) 1.02
Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord (2011) 1.01
Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry (2009) 0.99
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology (2008) 0.98
Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies. J Nucl Med (2013) 0.98
Somatostatin receptor scintigraphy in nasopharyngeal carcinoma. Clin Nucl Med (2008) 0.97
Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Prog Neurobiol (2012) 0.97
Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. Am J Med Genet A (2010) 0.97
A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology (2006) 0.96
The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol (2005) 0.96
A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. Mov Disord (2008) 0.95
Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci (2009) 0.94
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord (2013) 0.94
Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging (2012) 0.93
Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging (2009) 0.93
Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) (2004) 0.93
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry (2003) 0.93
Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol (2006) 0.92
Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology (2005) 0.92
Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord (2011) 0.91
Increased resting-state functional connectivity in obese adolescents; a magnetoencephalographic pilot study. PLoS One (2008) 0.91
Dopaminergic modulation of cortico-cortical functional connectivity in Parkinson's disease: an MEG study. Exp Neurol (2008) 0.91
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91
Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology (2013) 0.91
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2013) 0.90
Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. Arch Phys Med Rehabil (2005) 0.90
Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord (2009) 0.90
Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. J Clin Psychiatry (2011) 0.90
The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol (2008) 0.90
Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology (Berl) (2011) 0.89
No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage (2012) 0.89
Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats. Nucl Med Biol (2012) 0.88
Long-term outcome of thalamic deep brain stimulation in two patients with Tourette syndrome. J Neurol Neurosurg Psychiatry (2010) 0.88
Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry (2008) 0.88
Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor. Eur J Med Chem (2011) 0.88
Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. Parkinsonism Relat Disord (2012) 0.88
Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region. Mol Metab (2013) 0.88
Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. J Cereb Blood Flow Metab (2006) 0.87
Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. Mov Disord (2015) 0.86
Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse (2002) 0.86
Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Reduced neural connectivity but increased task-related activity during working memory in de novo Parkinson patients. Hum Brain Mapp (2015) 0.85
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. Am J Hematol (2009) 0.85
Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. Neuroimage (2005) 0.85
The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol (2009) 0.85
Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research. Brain Behav (2012) 0.85
Varenicline increases striatal dopamine D(2/3) receptor binding in rats. Addict Biol (2009) 0.85
Impairment of complex upper limb motor function in de novo Parkinson's disease. Parkinsonism Relat Disord (2007) 0.85
Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov Disord (2014) 0.85
Impulsivity in adult ADHD patients with and without cocaine dependence. Drug Alcohol Depend (2012) 0.85
Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology. J Psychopharmacol (2011) 0.85
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis (2010) 0.85
Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging (2014) 0.84
Striatal dopamine receptor binding in morbidly obese women before and after gastric bypass surgery and its relationship with insulin sensitivity. Diabetologia (2014) 0.84
Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J Psychopharmacol (2006) 0.84
Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology (2007) 0.84
VECTor: a preclinical imaging system for simultaneous submillimeter SPECT and PET. J Nucl Med (2012) 0.84
Localization of slow wave activity in patients with tumor-associated epilepsy. Brain Topogr (2003) 0.84
Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics (2009) 0.84
The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int J Methods Psychiatr Res (2005) 0.83